The first investigation of the central-type benzodiazepine (BZ) receptor density be~hre and following 2 months successful treatment with carbamazepine (CBZ) in a patient with temporal lobe epilepsy (TLE) using l~:~I-labelled Iomazenil (a specific lipophile central BZ receptor compound) and single photon emission tomography ISPET) is reported. First. a focal slowing of the EEG in the left temporal area was noted and a corresponding reduction of the central BZ density of the left temporal lobe was found. After 2 months of treatment the patient was symptom-free, and a normal BZ receptor density and no pathological EEG signs were found. The increase in central BZ receptor binding sites might be related to the anticonvulsant effects of CBZ mediated by the socalled peripheral BZ receptor sites.
INTRODUCTION
Presurgical imaging studies have shown that about 50~ of patients with focal seizures have no visible structural lesions in magnetic reasonance imaging (MRI) or computed tomography (CT) ~. Beside the invasive seizure monitoring with depth electrodes imaging methods with radiolabelled central benzodiazepine receptor ligands for positron emission tomography (PET} and single-photon emission tomography (SPET) may provide a noninvasive technique for the localization of seizure focus 2-6. Especially the latter is of interest since the SPET technique is less expensive and more available than PET. In vitro labelling of central-{using 125I-Ro 16-O154 = Iomazenil) and peripheral-type (using 3H-PK 11195) BZ receptors of epileptogenic tissue of patients with temporal lobe epilepsy (TLE) refractory to anti-epileptic medication and findings of mesial temporal sclerosis indicated a decrease of central-type and an increase of peripheraltype BZ receptor bindings sites 4. These changes seem to reflect the regional loss of neurons and a proliferation of glia, because the central-type is located on neurons and the peripheral-type is located on glia cells 4. The decreased density of these central-type GABAA-BZ receptors may also reflect a reduced inhibitory tone in the epileptic tissue. To investigate whether this finding changes in the course of the therapy especially in therapy responders we measured the central-type BZ receptor density in a patient with a medication-responding TLE.
PATIENT AND METHOD
A 37-year-old, otherwise healthy, female reporting a 5-year history of obscure daytime attacks and frequent fearful awakenings, was sent to our sleep laboratory. The patient reported about attacks which occurred up to five times a day. At the beginning of an attack she always felt strange followed by fear and movement arrest for a few seconds with lowering of consciousness. The seizures occurred also during sleep. The symptomatology initially classified as an anxiety disorder was unsucessfully treated with clonazepam (lmg/die) and pimozide (2mg/die) and the medication was therefore withdrawn several months ago~ We performed polysomnographic (PSG) and electroencephalographic (EEG) recordings and MRI scans. The central-type BZ receptor binding sites were measured with 123I-Iomazenil (a high selective central-type BZ receptor ligand (Kd0 0.5riM at 37°C)) and SPET before and after 2 months of successful treatment with carbamazepine (CBZ). An activity dose of 185 MBq 123I-Iomazenil was administered intravenously 120 minutes before the SPET measurement. For data acquisition a rotating gamma camera (Picker International) connected to a Picker Odyssey computer was used. A series of 64 images were collected at 6 ° increments for 30 seconds each into a 64 × 64 pixel matrix.
into account. The seizures were always followed by sleep stage wake. The 123I-Iomazenil SPETs were evaluated visually for asymmetries by two experienced raters, who were blind for the clinical data. In the transverse section of the patient we found a decreased tracer density in the left temporal lobe (Fig. 2, left side) .
Regarding the diagnostic tools, routine EEG, SPET and seizure classification revealed a localization-related epilepsy with complex partial seizures with a probable left frontotemporal origin.
After 2 weeks of treatment with carbamazepine 200 mg in the morning and 400 mg in the evening (serum level: 18.5 ~mol/1) the patient was free of seizures and the 2-month follow-up SPET showed a normalized symmetrical tracer distribution in both temporal lobes (Fig. 2,  right side) . In addition, the control EEGs showed no abnormalities under CBZ treatment.
RESULTS
The neurological examination, the MRI scan and the routine clinical laboratory techniques provided no pathological signs. In routine EEG we noted a focal slowing in the left temporal area.
During the video-monitored PSG, several complex partial seizures were recorded which clinically started with an epigastrial aura, followed by automatisms mainly of the upper extremities and lowering of consciousness. The seizures occurred six times out of sleep stage H, III and IV (Fig. 1) , the EEG was overlapped by increased EMG activity and could not be taken
DISCUSSION
The 123I-Iomazenil SPET of the untreated patient indicated a reduced binding of tracer at the left temporal lobe. This result could be due to changes in the density or sensitivity of benzodiazepine receptors or result from an in vivo competition of an endogenous ligand with the radioligand as demonstrated in vivo with dopamine receptor ligands. 7 First, the reduction of central BZ receptor density found in neurosurgical preparations of epileptic tissue points to a reduction of BZ receptor binding sites and not to a loss of sensitivity in our case 4. Second, there is no reason why an endogenous receptor ligand should more effectively compete for He proposed that these non-PV-expressing neurons in the GABA pyramidal basket cells may characterize them as dormant cells. Therefore the decreased GABA-mediated inhibition in TLE may be related to changes in the functional status and not to a loss of GABA neurons. Our data, which show a normalized symmetrical distribution of the central-type BZ receptor density after the successful treatment with CBZ, support the hypothesis of changes in the functional status of GABA-ergic neurons. Nevertheless, there may be a difference between therapy responders and non-responders, especially when mesial sclerosis is present 4. The occurrence of a symmetrical BZ receptor distribution under successful anticonvulsant treatment with CBZ could possibly be mediated by a glial neuronal interaction, because its known that in part the anticonvulsant effects of CBZ are mediated through the so-called peripheral BZ receptor sites which are located on glial cells '°. Whether the reduction of central BZ receptors is constant during therapy in non-responders remains to be clarified. In our opinion, our data underline that 123I-Iomazenil-SPET is an appropriate method for such measurements.
